Chapter 63 The future of stroke prevention by risk factor modification

Handbook of Clinical Neurology

Volumn 94, Issue , 2008, Pages 1261-1276

  Gorelick, Philip B ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66049123336     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(08)94063-X     Document Type: Review

References (125)

1. Albers G.W., Amarenco P., Easton J.D., et al. Antithrombotic and thrombolytic therapy for ischemic stroke. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 483S-512S
2. Alberts M.J., Hademenos G., Latchaw R.E., et al. Recommendations for the establishment of primary stroke centers. JAMA 283 (2000) 3102-3109
3. Alberts M.J., Latchaw R.E., Selman W.R., et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke 36 (2005) 1597-1616
4. Anderson J.L. Infection, antibiotics, and atherothrombosis-end of the road or new beginnings?. N Engl J Med 352 (2005) 1706-1709
5. Atwood K., Colditz G.A., and Kawachi I. From public health science to prevention policy: placing science in its social and political contexts. Am J Public Health 87 (1997) 1603-1606
6. Axisa B., Loftus I.M., Naylor A.R., et al. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 33 (2002) 2858-2865
7. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 109 (2004) 837-842
8. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation (abstract 2979) 110 (2004) 641
9. Barnett H.J.M., and Meldrum H.E. Surgical measures to prevent stroke. In: Norris J.W., and Hachinski V. (Eds). Stroke Prevention (2001), Oxford University Press, New York 211-235
10. Blakely D.D., Odone E.E., Hasselbad V., et al. Non-invasive carotid artery testing: a meta-analytic review. Ann Intern Med 120 (1995) 360-367
11. Boden-Albala B., Sacco R.L., Lee H.S., et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan study. Stroke 39 1 (2008) 30-35
12. Boersma E., Mercado N., Poldermans D., et al. Acute myocardial infarction. Lancet 361 (2003) 847-858
13. Buekens P., Keusch G., Belizan J., et al. Evidence-based global health. JAMA 291 (2004) 2639-2641
14. Buse J.B., Ginsberg H.N., Bakris G.L., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the. American Diabetes Association 115 (2007) 114-126
15. Camilo O., and Goldstein L.B. Statewide assessment of hospital-based stroke prevention and treatment services in North Carolina. Changes over the last 5 years. Stroke 34 (2003) 2945-2950
16. Cannon C.P., Braunwald E., McCabe C.H., et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 352 (2005) 1646-1654
17. Canto J.G., and Iskandrian A.E. Major risk factors for cardiovascular disease. Debunking the "only 50%" myth. JAMA 290 (2003) 947-949
18. Caples S.M., Gami A.S., and Somers V.K. Obtructive sleep apnea. Ann Intern Med 142 (2005) 187-197
19. Caslake M.J., and Packard C.J. Lipoprotein-associated phospholipase A2 (platelet- activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 14 (2003) 347-352
20. Chobanian A., Bakris G., Black H., et al., The National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289 (2003) 2560-2572
21. Christensen K., and Murray J.C. What genome-wide association studies can do for medicine. N Engl J Med 356 (2007) 1094-1097
22. Cipollone F., Fazia M., Mincione G., et al. Increased expression of transforming growth factor-B1 as a stabilizing factor in human atherosclerotic plaques. Stroke 35 (2004) 2253-2257
23. D'Agostino R.B., Wolf P.A., Belanger A.J., et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 25 (1994) 40-43
24. Desvarieux M., Schwahn C., Volzke H., et al. Gender differences in the relationship between periodontal disease, tooth loss and atherosclerosis. Stroke 35 (2004) 2029-2035
25. Dominiczak A.F., and McBride M.W. Genetics of common polygenic stroke. Nat Genet 35 (2003) 116-117
26. Dwyer J.H., Allayee H., Dwyer K.M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350 (2004) 29-37
27. Elkind M.S.V. Implications of stroke prevention trials. Treatment of global risk. Neurology 65 (2005) 17-21
28. Engstrom G., Lind P., Hedblad B., et al. Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke 33 (2002) 2744-2749
29. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 273 (1995) 1421-1428
30. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
31. Favre A., Monpere C., Voyer C., et al. How to improve primary prevention in asymptomatic high risk subjects?. Eur Heart J 6 (2004) J59-J63
32. Giles T.D. The New Definition of Hypertension. Presented at Plenary Session I, American Society of Hypertension 20th Annual Scientific Meeting and Exposition San Francisco, CA, May 15th (2005)
33. Goldstein L.B. Do the Brain Attack Coalition's criteria for stroke centers improve care for ischemic stroke?. Neurology 64 (2005) 762-763
34. Goldstein L., Adams R., Becker K., et al. Primary prevention of ischemic stroke. A statement for health care professionals from the Stroke Council of the American Heart Association. Circulation 103 (2001) 163-182
35. Goldstein L.B., Adams R., Alberts M.A., et al. Primary prevention of ischemic stroke. A guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 37 (2006) 1538-1633
36. Gordon R.L., Gerzoff R.B., and Richards T.B. Determinants of US local health department expenditures, 1992-1993. Am J Public Health 87 (1997) 91-95
37. Gorelick P.B. Stroke prevention: an opportunity for efficient use of health care resources in the coming decade. Stroke 25 (1994) 220-224
38. Gorelick P.B. Stroke prevention. Arch Neurol 52 (1995) 347-355
39. Gorelick P.B. Stroke prevention: windows of opportunity and failed expectations? A discussion of modifiable cardiovascular risk factors and a prevention proposal. Neuroepidemiology 16 (1997) 163-173
40. Gorelick P.B. Carotid endarterectomy. Where do we draw the line?. Stroke 30 (1999) 1745-1750
41. Gorelick P.B. Primary and secondary stroke prevention. In: Bogousslavsky J. (Ed). Drug Therapy for Stroke Prevention (2001), Taylor and Francis, New York 14-34
42. Gorelick P.B. Prevention and screening programs. In: Norris J.W., and Hachinski V. (Eds). Stroke Prevention (2001), Oxford University Press, New York 117-136
43. Gorelick P.B. New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol 1 (2002) 149-156
44. Gorelick P.B. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. An invited review. Stroke 33 (2002) 862-875
45. Gorelick P.B. An integrated approach to stroke prevention. In: Chalmers J. (Ed). Clinician's Manual on Blood Pressure and Stroke Prevention. 3rd edn (2002), Scientific Press, London 55-65
46. Gorelick P.B. North American perspective of antiplatelet agents. In: Barnett H.J.M., Bogousslavsky J., and Meldrum H. (Eds). Ischemic Stroke (2003), Lippincott Williams and Wilkins, New York 281-291
47. Gorelick P.B. CONTINUUM: Lifelong learning in neurology. Stroke Prevention (2005), American Academy of Neurology August
48. Gorelick P.B., Sacco R.L., Smith D.B., et al. Prevention of a first stroke. A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 281 (1999) 1112-1120
49. Grau A.J., Becher H., Ziegler C.M., et al. Periodontal disease as a risk factor for ischemic stroke. Stroke 35 (2004) 496-501
50. Grau A.J., Fischer B., Barth C., et al. Influenza vaccination is associated with a reduced risk of stroke. Stroke 36 (2005) 1501-1506
51. Grayston J.T., Kronmal R.A., Jackson L.A., et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 352 (2005) 1637-1645
52. Greenland P., Knoll M.D., Stamler J., et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 290 (2003) 891-897
53. Gretarsdottir S., Thorleifsson G., Reynisdottir S., et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 35 (2003) 131-138
54. Grol R., and Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet 362 (2003) 1225-1230
55. Grundy S.M., Pasternak R., Greenland P., et al. Assessment of cardiovascular risk by use of multiple-risk-factor association equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100 (1999) 1481-1492
56. Hackam D.G., and Anand S.S. Emerging risk factors for atherosclerotic vascular disease. A critical review of the evidence. JAMA 290 (2003) 932-940
57. Hankey G. Policy and practice in the prevention of stroke: between the ideal and the affordable. In: Norris J.W., and Hachinski V. (Eds). Stroke Prevention (2001), Oxford University Press, New York 313-334
58. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
59. Haynes R.B., McDonald H.P., and Garg A.X. Helping patients follow prescribed treatment. Clinical applications. JAMA 288 (2002) 2880-2883
60. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 3 (2004) 233-239
61. Jencks S.F., Huff E.D., and Cuerdon T. Change in the quality of care deliveried to Medicare beneficiaries, 1998-1999 to 2000-2001. JAMA 289 (2003) 305-312
62. Joseph L.N., Kase C.S., Beiser A.S., et al. Mild blood pressure elevation and stroke. Proceedings of the 23rd International Conference on Stroke and Cerebral Circulation, Orlando (abstract) (1998)
63. Kane R.L., Johnson P.E., Town R.J., et al. Economic Incentives for Preventive Care. Summary, Evidence Report/Technology Assessment: Number 101 (2004), Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/epcsums/ecrinscum.htm AHRQ Publication Number 04-E024-1, August 2004
64. Kaneko Y., Floras J.S., Kengo U., et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 348 (2003) 1233-1241
65. Kernan W.N., Inzucchi S.E., Viscoli C.M., et al. Insulin resistance and risk for stroke. Neurology 59 (2002) 809-815
66. Khot U.N., Khot M.B., Bajzer C.T., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290 (2003) 898-904
67. Koenig W., Khuseyinova N., Lowel H., et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population. Results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908
68. Koren-Morag N., Goldhourt U., and Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack. A prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 36 (2005) 1366-1371
69. Kullo I.J., and Ballantyne C.M. Conditional risk factors of atherosclerosis. Mayo Clin Proc 80 (2005) 219-230
70. Lakka H.M., Laaksonen D.F., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
71. Law M.R., Wald N.J., Morris J.K., et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ 326 (2003) 1427
72. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326 (2003) 1423
73. Lawes C.M.M., Bennett D.A., Feigin V.L., et al. Blood pressure and stroke. An overview of published reviews. Stroke 35 (2004) 1024-1033
74. Lee T.T., Salomon N.A., Heidenreich P.A., et al. Cost-effectiveness of screening for carotid stenosis in asymptomatic patients. Ann Intern Med 126 (1997) 337-346
75. Levy D. The new definition of hypertension: epidemiological considerations. Presented at Plenary Session I, American Society of Hypertension 20th Annual Scientific Meeting and Exposition, San Francisco, CA, May 15th (2005)
76. Lindsberg P.J., and Grau A.J. Inflammation and infections as risk factors for ischemic stroke. Stroke 34 (2003) 2518-2532
77. Lloyd-Jones D.M., Nam B., D'Agostino R.B., et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. A prospective study of parents and offspring. JAMA 291 (2004) 2204-2211
78. Lupski J.R. Structural variation in the human genome. N Engl J Med 356 (2007) 1169-1171
79. Magyar M.T., Szikszai Z., Balla J., et al. Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke 34 (2003) 58-63
80. Malhotra A., and White D.P. Obstructive sleep apnea. Lancet 360 (2002) 237-245
81. Manolio T. Novel risk markers and clinical practice. N Engl J Med 349 (2003) 1587-1589
82. Marin J.M., Carrizo S.J., Vicente E., et al. Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365 (2005) 1046-1053
83. McArdle N., Riha R.L., Vennelle M., et al. Sleep-disordered breathing as a risk factor for cerebrovascular disease. A case-control study in patients with transient ischemic attacks. Stroke 34 (2003) 2916-2921
84. McDonald H.P., Garg A.X., and Haynes R.B. Interventions to enhance patient adherence to medication prescriptions. Scientific review. JAMA 288 (2002) 2868-2879
85. Milionis H.J., Rizos E., Goudevenous J., et al. Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 36 (2005) 1372-1376
86. Mohsenin V. Sleep-related breathing disorders and risk of stroke. Stroke 32 (2001) 1271-1278
87. Mosca L., Banka C.L., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
88. Moser M. Clinical Management of Hypertension (2004), Professional Communications, Inc, New York 17-19
89. MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomized controlled trial. Lancet 363 (2004) 1491-1502
90. Mulrow C., and Kussmaul W. The middle-aged and older American: wrong prototype for a preventive pill?. Ann Intern Med 142 (2005) 467-468
91. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
92. Nuotio K., Lindsberg P.J., Carpen O., et al. Adhesion molecule expression in symptomatic and asymptomatic carotid stenosis. Neurology 60 (2003) 1890-1899
93. Nuwer M. On the process of evaluating proposed new diagnostic EEG tests. Brain Topogr 4 (1992) 243-247
94. O'Donnell C.J. Translating the human genome project into prevention of myocardial infarction and stroke-getting close?. JAMA 293 (2005) 2277-2279
95. Obuchowski N.A., Modic M.T., Magdenic M., et al. Assessment of the efficacy of noninvasive testing for patients with asymptomatic neck bruits. Stroke 28 (1997) 1330-1339
96. Oei H., Van der Meer I., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke. The Rotterdam Study. Circulation 111 (2005) 570-575
97. Packard C.J., O'Reilly D.S.J., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 343 (2000) 1148-1155
98. Perry J.R., Szalai J.P., Norris J.W., and for the Canadian Stroke Consortium. Consensus against both endarterectomy and routine screening for asymptomatic carotid artery stenosis. Arch Neurol 54 (1997) 25-28
99. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1902-1913
100. Pussinen P.J., Alfthan G., Rissanen H., et al. Antibodies to periodontal pathogens and stroke risk. Stroke 35 (2004) 2020-2023
101. Pyorala M., Miettinen H., Laasko M., et al. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up of the Helsinki Policemen Study. Stroke 29 (1998) 1860-1866
102. Radziszewska B., Hart R.G., Wolf P.A., et al. Clinical research in primary stroke prevention: needs, opportunities, and challenges. Neuroepidemiology 25 (2005) 91-104
103. Rose G. The Strategy of Preventive Medicine (1994), Oxford University Press, New York 1-138
104. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
105. Ruland S., Gorelick P.B., Schneck M., et al. Acute stroke care in Illinois. A statewide assessment of diagnostic and treatment capabilities. Stroke 33 (2002) 1334-1340
106. Sacco R.L., Adams R., Albers G., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 37 (2006) 577-617
107. Sackett D.L., Haynes R.B., and Tugwell P. Clinical Epidemiology. A Basic Science for Clinical Medicine Vol. 139 (1985), Little Brown, Boston 302-310
108. Schwamm L.H., Pancioli A., Acker J.E., et al. Recommendations of the establishment of stroke systems of care. Recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. Stroke 36 (2005) 690-703
109. Shamsuzzaman A., Gersh B.J., and Somers V.K. Obstructive sleep apnea. Implications for cardiac and vascular disease. JAMA 290 (2003) 1906-1914
110. Smeeth L., Thomas S.L., Hall A.J., et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 351 (2004) 2611-2618
111. Sox H., Stern S., Owens D., et al. Assessment of Diagnostic Technology in Health Care. Rational, Methods, Problems and Directions (1989), Institute of Medicine National Academy Press, Washington, DC 8-54
112. Spence J.D., and Norris J. Infection, inflammation, and atherosclerosis. Stroke 34 (2003) 333-334
113. Stamler J., Stamler R., Neaton J.D., et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy. Findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 282 (1999) 2012-2018
114. Sudhir K. Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) is an Independent Risk Factor of Coronary Heart Disease. Massachusetts Medical Society (2000)
115. Tipton M.L., and Fleming M. Stroke prevention in managed care: a five-dimensional health improvement model. In: Gorelick P.B., and Alter M.A. (Eds). The Prevention of Stroke (2002), Parthenon Publishing, New York 123-130
116. Tishler P.V., Larkin E.K., Schluchter M.D., et al. Incidence of sleep-disordered breathing in an urban adult population. The relative importance of risk factors in the development of sleep-disordered breathing. JAMA 289 (2003) 2230-2237
117. Van der Meer I.M., de Maat M.P.M., Hak A.E., et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree. The Rotterdam Study. Stroke 33 (2002) 2750-2755
118. Vasan R.S., Sullivan L.M., Wilson P.W.F., et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 142 (2005) 393-402
119. Wald N.J., and Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 (2003) 1419
120. Wattigney W.A., Croft J.B., Mensah G.A., et al. Establishing data elements for the Paul Coverdell National Acute Stroke Registry. Part 1: Proceedings of an expert panel. Stroke 34 (2003) 151-156
121. Wilson J.F. The promise of disease proteomics: faster detection, diagnosis, and drug development. Ann Intern Med 140 (2004) 317-319
122. Wood D.A., Kotseva K., Jennings C., et al. EUROACTION: a European Society of Cardiology demonstration in preventive cardiology. A cluster randomized controlled trial of a multi-disciplinary preventive cardiology programme for coronary patients, asymptomatic high risk individuals and their families. Summary of design, methodology and outcomes. Eur Heart J 6 (2004) J3-J15
123. Yach D., Hawkes C., Gould C.L., et al. The global burden of chronic diseases. Overcoming impediments to prevention and control. JAMA 291 (2004) 2616-2622
124. Young T., Skatrud J., and Peppard P.E. Risk factors for obstructive sleep apnea in adults. JAMA 291 (2004) 2013-2016
125. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952